A detailed history of Entry Point Capital, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Entry Point Capital, LLC holds 10,923 shares of CYTK stock, worth $480,502. This represents 0.23% of its overall portfolio holdings.

Number of Shares
10,923
Previous 8,825 23.77%
Holding current value
$480,502
Previous $465,000 10.32%
% of portfolio
0.23%
Previous 0.27%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$46.36 - $58.62 $97,263 - $122,984
2,098 Added 23.77%
10,923 $513,000
Q3 2024

Nov 13, 2024

BUY
$51.22 - $60.16 $452,016 - $530,912
8,825 New
8,825 $465,000
Q1 2024

May 14, 2024

BUY
$63.75 - $108.06 $66,937 - $113,463
1,050 New
1,050 $73.6 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.14B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Entry Point Capital, LLC Portfolio

Follow Entry Point Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entry Point Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Entry Point Capital, LLC with notifications on news.